The purpose of this study is to compare 4 different combinations of anti-HIV drugs and to determine the number of people whose HIV blood levels decrease to 200 copies/ml or less while on the treatment. This study evaluates the safety of these drug combinations, which include an experimental protease inhibitor (PI), amprenavir. Despite the success that many patients have had with PI treatment regimens, there is still a possibility that patients receiving PIs may continue to have high HIV blood levels. Because of this possibility, alternative drug combinations containing PIs are being studied. It appears that amprenavir, when taken with 3 or 4 other anti-HIV drugs, may be effective in patients with prior PI treatment experience.
Name: Indinavir sulfate
Type: Drug
Name: Abacavir sulfate
Type: Drug
Name: Amprenavir
Type: Drug
Name: Nelfinavir mesylate
Type: Drug
Name: Efavirenz
Type: Drug
Name: Levocarnitine
Type: Drug
Name: Adefovir dipivoxil
Type: Drug
Name: Saquinavir
Type: DrugThere is one SNP
Amprenavir (APV) is an attractive candidate to investigate as part of salvage regimens because: 1) it has substantial antiretroviral activity; 2) there are preliminary in vitro and in vivo data that suggest that resistance to this agent may be mediated in part by a unique mutation (I50V); and 3) its cross-resistance profile to the approved PIs is uncertain. --- I50V ---